RxDoctor Payments Data

Helene Lee, MD

Family Medicine · Elkton, MDNPI 1750587408

Payments from drug & device makers

$7,574in general payments, 2019–2025

Across 377 payments — averaging $20.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Boehringer Ingelheim$700
  • Novo Nordisk$651
  • Lilly USA, LLC$648
  • Pfizer$597
  • AbbVie$532
  • plus $3K from 35 others

What the payments were for

  • Food & beverage$7,566100%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,574 in reported general payments places this provider in the 90th percentile of 1,193 family medicine providers in Maryland.

See all family medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$95,833
Medicare patients
227
Services billed
1,258

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide24$50,265
OzempicSemaglutide32$49,749
MounjaroTirzepatide29$39,763
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$27,354
FarxigaDapagliflozin Propanediol17$22,227
JardianceEmpagliflozin18$18,445
MyrbetriqMirabegron23$16,532
EliquisApixaban15$14,912
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$7,294
Risedronate Sodium33$2,871
Dexlansoprazole DrDexlansoprazole12$2,622
Atorvastatin Calcium189$2,161
Rosuvastatin Calcium136$2,085
Metoprolol Succinate100$1,875
Omeprazole110$1,832

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$648$90,02853 claims
Novo NordiskOzempic$651$49,74932 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,006$29,52129 claims
GSKTrelegy Ellipta$473$27,35418 claims
Boehringer IngelheimJardiance$700$18,44518 claims
Astellas Pharma US IncMyrbetriq$229$16,53223 claims
PfizerEliquis$597$14,91215 claims
AbbVieSynthroid$532$80517 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,193 family medicine providers in Maryland.

Other family medicine in Elkton

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →